Robert Malenka Sells 12,116 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 12,116 shares of the stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $18.21, for a total value of $220,632.36. Following the completion of the sale, the director directly owned 339,254 shares of the company’s stock, valued at $6,177,815.34. The trade was a 3.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Maplight Therapeutics Price Performance

Shares of Maplight Therapeutics stock opened at $17.92 on Friday. Maplight Therapeutics, Inc. has a 1 year low of $12.24 and a 1 year high of $21.55. The stock has a market cap of $813.03 million and a P/E ratio of -0.48. The stock’s fifty day simple moving average is $17.99.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Institutional Trading of Maplight Therapeutics

Institutional investors have recently bought and sold shares of the company. Strs Ohio acquired a new stake in Maplight Therapeutics in the fourth quarter valued at $53,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Maplight Therapeutics in the 4th quarter valued at about $70,000. New York State Common Retirement Fund acquired a new position in Maplight Therapeutics during the fourth quarter worth about $93,000. MetLife Investment Management LLC purchased a new stake in shares of Maplight Therapeutics in the fourth quarter valued at about $172,000. Finally, Walleye Capital LLC acquired a new stake in shares of Maplight Therapeutics in the fourth quarter valued at approximately $205,000.

Analyst Upgrades and Downgrades

MPLT has been the topic of several analyst reports. Wall Street Zen raised shares of Maplight Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Jefferies Financial Group assumed coverage on Maplight Therapeutics in a report on Friday, November 21st. They issued a “buy” rating and a $32.00 price objective on the stock. Stifel Nicolaus assumed coverage on Maplight Therapeutics in a research note on Friday, November 21st. They set a “buy” rating and a $28.00 target price for the company. Morgan Stanley initiated coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued an “overweight” rating and a $34.00 price target on the stock. Finally, Zacks Research raised Maplight Therapeutics to a “hold” rating in a report on Monday, November 24th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Maplight Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $31.00.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.